Merck (MRK) said Monday 23 nov 2020 it plans to acquire privately held OncoImmune for $425 million in cash, gaining rights to an under-the-radar drug that has shown striking results in hospitalized patients with Covid. The treatment was shown to reduce the risk of respiratory failure or death by more than 50% in patients hospitalized with Covid and requiring oxygen. (CNBC)

DOES ANYONE KNOW THIS DRUG??